Adrian W. Quartel - 14 Mar 2023 Form 4 Insider Report for Acer Therapeutics Inc.

Reporting relationship: Chief Medical Officer
Issuer ticker: N/A
Reported as of: 14 Mar 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Mar 2023, 16:50:15 UTC
Prior SEC filing: 23 Feb 2022
Next SEC filing: 27 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Harry S. Palmin, Attorney-in-Fact

Key filing fact

Adrian W. Quartel filed Form 4 for Acer Therapeutics Inc. on 16 Mar 2023.

Key facts

This page summarizes Adrian W. Quartel's Form 4 filing for Acer Therapeutics Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Mar 2023, 16:50.

Change

Previous filing in this sequence was filed on 23 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACER transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +30,000
Change %
Price: $0.000000
Shares after: 30,000
Date: 14 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $1.67
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option, which is made as part of the issuer's 2023 annual compensation cycle, vests and becomes exercisable over four years as follows: 25% of the shares vest on March 14, 2024, and the remaining 75% of the shares vest quarterly over the remaining three years.